Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

@inproceedings{Abdullah2012DermatologicTF,
  title={Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management},
  author={Shaad E. Abdullah and Missak Haigentz and Bilal Piperdi},
  booktitle={Chemotherapy research and practice},
  year={2012}
}
Epidermal growth factor receptor (EGFR) inhibition has now been well established as an effective treatment for various cancers. The EGFR belongs to the ErbB family of tyrosine kinase receptors which regulate tumor cell differentiation, survival and proliferation. Activation of EGFR drives tumorigenesis in lung, head and neck, colorectal and pancreatic cancers. Irrespective of the type of cancer being treated and the mechanism by which tumor EGFR drives tumorigenesis, the major side effect of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 75 references

Imprime PGG improves survival in KRAS mutant colorectal cancer patients

  • NS N.H.Segal, P. Gada, L. M. Marsh, M. A. Gargano, LS M.L.Patchen
  • European Society for Medical Oncology (ESMO) 13th…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…